Is Target a Dividend King?
Popular retail giant Target Corporation (NYSE:TGT) has been in a…
Buy
55
OMCL Quote, Financials, Valuation and Earnings
Last price:
$42.30
Seasonality move
:
1.05%
Day range:
$41.36 - $42.48
52-week range:
$25.12 - $55.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.83x
P/B ratio:
1.59x
Volume:
289.1K
Avg. volume:
506.5K
1-year change:
23.85%
Market cap:
$2B
Revenue:
$1.1B
EPS (TTM):
-$0.39
Analysts' Opinion
-
Consensus RatingOmnicell has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $55.43, Omnicell has an estimated upside of 30.98% from its current price of $42.32.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $44.00 representing 100% downside risk from its current price of $42.32.
Fair Value
-
According to the consensus of 8 analysts, Omnicell has 30.98% upside to fair value with a price target of $55.43 per share.
OMCL vs. S&P 500
-
Over the past 5 trading days, Omnicell has underperformed the S&P 500 by -5.31% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Omnicell does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Omnicell revenues have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter Omnicell reported revenues of $282.4M.
Earnings Growth
-
Omnicell has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Omnicell reported earnings per share of $0.19.
Enterprise value:
1.9B
EV / Invested capital:
--
Price / LTM sales:
1.83x
EV / EBIT:
--
EV / Revenue:
1.83x
PEG ratio (5yr expected):
-3.94x
EV / Free cash flow:
16.49x
Price / Operating cash flow:
16.44x
Enterprise value / EBITDA:
34.91x
Gross Profit (TTM):
$434.6M
Return On Assets:
-0.78%
Net Income Margin (TTM):
-1.66%
Return On Equity:
-1.47%
Return On Invested Capital:
-1%
Operating Margin:
2.32%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.3B | $1.2B | $1.1B | $298.7M | $282.4M | |
| Gross Profit | $616.5M | $513.2M | $434.6M | $132M | $122.3M | |
| Operating Income | $47.6M | -$49.9M | -$35.4M | $3.7M | $6.6M | |
| EBITDA | $145.2M | $46.6M | $55.8M | $27.3M | $28.1M | |
| Diluted EPS | $1.02 | -$0.77 | -$0.39 | $0.12 | $0.19 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $963.4M | $888.7M | $849.1M | $913.8M | $1B | |
| Total Assets | $1.7B | $2.1B | $2.2B | $2.2B | $2.3B | |
| Current Liabilities | $233.9M | $338.7M | $376.7M | $369.4M | $961.5M | |
| Total Liabilities | $800.9M | $940.1M | $1B | $1B | $1.1B | |
| Total Equity | $918.4M | $1.1B | $1.1B | $1.2B | $1.2B | |
| Total Debt | $462.1M | $482.8M | $565.8M | $568.9M | $572M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $55.3M | $224.8M | $169.8M | $57M | $22.8M | |
| Cash From Investing | -$233.8M | -$59.9M | -$51.6M | -$14.2M | -$13.3M | |
| Cash From Financing | -$17.8M | $13.9M | $12M | $2.8M | $3.6M | |
| Free Cash Flow | -$4.6M | $165M | $118.2M | $42.8M | $9.4M | |
OMCL
Sector
Market Cap
$2B
$46.7M
Price % of 52-Week High
75.92%
46.54%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
23.85%
-33.88%
Beta (5-Year)
0.777
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$43.74
200-day SMA
Buy
Level
$37.31
Bollinger Bands (100)
Sell
Level
41.87 - 47.23
Chaikin Money Flow
Buy
Level
70.5M
20-day SMA
Sell
Level
$44.28
Relative Strength Index (RSI14)
Sell
Level
39.08
ADX Line
Sell
Level
25.89
Williams %R
Neutral
Level
-76.4706
50-day SMA
Sell
Level
$46.16
MACD (12, 26)
Sell
Level
-0.74
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
12.3M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.9885)
Buy
CA Score
(Annual)
Level (-0.2296)
Buy
Beneish M-Score
(Annual)
Level (-3.0193)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-0.9634)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
Stock Forecast FAQ
In the current month, OMCL has received 3 Buy ratings 5 Hold ratings, and 0 Sell ratings. The OMCL average analyst price target in the past 3 months is $55.43.
-
Where Will Omnicell Stock Be In 1 Year?
According to analysts, the consensus estimate is that Omnicell share price will rise to $55.43 per share over the next 12 months.
-
What Do Analysts Say About Omnicell?
Analysts are divided on their view about Omnicell share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Omnicell is a Sell and believe this share price will drop from its current level to $44.00.
-
What Is Omnicell's Price Target?
The price target for Omnicell over the next 1-year time period is forecast to be $55.43 according to 8 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is OMCL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Omnicell is a Hold. 5 of 8 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of OMCL?
You can purchase shares of Omnicell via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Omnicell shares.
-
What Is The Omnicell Share Price Today?
Omnicell was last trading at $42.30 per share. This represents the most recent stock quote for Omnicell. Yesterday, Omnicell closed at $42.32 per share.
-
How To Buy Omnicell Stock Online?
In order to purchase Omnicell stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is COWZ ETF a Good Investment?
There’s a reason even Warren Buffett advocates his heirs to…
3 Stocks Buffett Is Betting On
Warren Buffett appeared to take a hard look at the…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 39x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
40
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
61
ITCI alert for Jan 14
Intra-Cellular Therapies [ITCI] is down 0.26% over the past day.
Sell
30
ESTA alert for Jan 14
Establishment Labs Holdings [ESTA] is down 1.51% over the past day.
Buy
72
DJT alert for Jan 14
Trump Media & Technology Group [DJT] is down 8.25% over the past day.
